同和药业：公司上市以来聚焦主业稳健经营

Core Viewpoint - Tonghe Pharmaceutical (300636) has focused on its main business since its listing, demonstrating steady operations and diligent management, leading to continuous growth in revenue and net profit [1] Group 1: Business Performance - The company has maintained a consistent increase in both operating income and net profit over the years [1] - Efforts have been made to reduce costs and improve efficiency while continuously investing in research and development [1] Group 2: Investor Relations - The management emphasizes market value management and engages with investors through various forms of interaction [1] - The company actively communicates and promotes its investment value to the capital market [1] Group 3: Shareholder Returns - Tonghe Pharmaceutical has implemented cash dividends to reward investors annually [1]